Nontaya Nakkam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7961903/publications.pdf

Version: 2024-02-01

20 papers	523 citations	932766 10 h-index	794141 19 g-index
20 all docs	20 docs citations	20 times ranked	551 citing authors

#	Article	IF	Citations
1	Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and Genomics, 2016, 26, 225-234.	0.7	94
2	Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13. Pharmacogenetics and Genomics, 2017, 27, 429-437.	0.7	87
3	The Medication Risk of Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. Clinical Pharmacology and Therapeutics, 2019, 105, 112-120.	2.3	54
4	<scp>HLA</scp> Alleles and <scp>CYP</scp>2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. Clinical Pharmacology and Therapeutics, 2019, 105, 476-485.	2.3	53
5	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. Journal of Allergy and Clinical Immunology, 2021, 147, 1402-1412.	1.5	46
6	Genetic Association of Coâ€Trimoxazoleâ€Induced Severe Cutaneous Adverse Reactions Is Phenotypeâ€Specific: HLA Class I Genotypes and Haplotypes. Clinical Pharmacology and Therapeutics, 2020, 108, 1078-1089.	2.3	34
7	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	2.2	29
8	Cross-reactivity between vancomycin, teicoplanin, and telavancin in patientsÂwith HLA-Aâˆ—32:01â€“positive vancomycin-induced DRESS sharing an HLA class II haplotype. Journal of Allergy and Clinical Immunology, 2021, 147, 403-405.	1.5	26
9	Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and Genomics, 2017, 27, 255-263.	0.7	25
10	HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population. Frontiers in Genetics, 2018, 9, 277.	1.1	24
11	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Frontiers in Immunology, 2021, 12, 658593.	2.2	14
12	Comparison between the HLA-B<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>âˆ—</mml:mo></mml:mrow></mml:msup></mml:math>58â€‰:â€‰01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	12
13	Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine. British Journal of Clinical Pharmacology, 2022, 88, 773-786.	1.1	8
14	The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. Drug Metabolism and Pharmacokinetics, 2015, 30, 295-304.	1.1	5
15	Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations. Frontiers in Pharmacology, 2021, 12, 784712.	1.6	5
16	Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients. Journal of Pediatric Genetics, 2021, 10, 029-034.	0.3	2
17	Considerations for cross-reactivity between vancomycin and other glycopeptides. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3233.	2.0	2
18	Prevalence of CYP2C19, CYP3A4 and FMO3 genetic polymorphisms in healthy northeastern Thai volunteers. ScienceAsia, 2020, 46, 397.	0.2	1

#	Article	IF	Citations
19	Comparative pharmacodynamic effects of two clopidogrel formulations under steady-state conditions in healthy Thai volunteers. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 177-185.	0.3	1
20	NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine. Drug Metabolism and Pharmacokinetics, 2021, 43, 100436.	1.1	1